BBNX Beta Bionics, Inc.

Nasdaq www.betabionics.com


$ 27.05 $ -0.85 (-3.05 %)    

Wednesday, 05-Nov-2025 11:08:33 EST
QQQ $ 622.35 $ 3.87 (0.63 %)
DIA $ 470.65 $ -0.21 (-0.05 %)
SPY $ 677.35 $ 2.30 (0.34 %)
TLT $ 89.06 $ -0.45 (-0.5 %)
GLD $ 366.09 $ -0.36 (-0.1 %)
$ 27.81
$ 27.26
$ 26.95 x 209
$ 27.10 x 6
$ 26.87 - $ 27.39
$ 8.89 - $ 30.47
549,009
na
1.21B
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-28-2025 09-30-2025 10-Q
2 07-29-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-25-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $26 to $33.

Core News & Articles

Stifel analyst Jonathan Block reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $26 to $31.

Core News & Articles

Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from...

Core News & Articles

Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target f...

Core News & Articles

Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $88.000 million-$93.000 million to $96.500 million vs $91.355 milli...

Core News & Articles

Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.44) ...

Core News & Articles

Stifel analyst Jonathan Block reinstates Beta Bionics (NASDAQ:BBNX) with a Buy and announces $26 price target.

Core News & Articles

Goldman Sachs analyst David Roman upgrades Beta Bionics (NASDAQ:BBNX) from Neutral to Buy and raises the price target from $...

Core News & Articles

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...

Core News & Articles

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...

Core News & Articles

Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $15 to $17.

Core News & Articles

Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $82.00 million-$87.00 million to $88.00 million-$93.00 million vs $...

Core News & Articles

Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION